Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30
Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.
Stocks · News reference
Beta Bionics Announces Partnership To Integrate iLet Insulin Pump With Senseonics' Eversense 365 Glucose Monitor, Expects Q4 2026 Launch
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.
Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28
Wells Fargo analyst Larry Biegelsen initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Overweight rating and announces Price Target of $28.